Bahrain: Zantac and Apo-Ranitidine Withdrawn From Market

Bahrain: Zantac and Apo-Ranitidine Withdrawn From Market
National Health Regulatory Authority (NHRA) announced the withdrawal of all forms of Zantac and Apo-Ranitidine from the market

Bahrain’s National Health Regulatory Authority (NHRA) announced the withdrawal of all forms of Zantac and Apo-Ranitidine from the market as they contain N-nitrosodimethylamine (NDMA).

The move comes after a study by the US Food and Drug Administration revealed that NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests.

The Authority has also suspended the importation of all other medicines containing ranitidine until further notice.

NHRA indicated that it is coordinating and liaising with the Saudi Food and Drug Authority FDA to monitor the results of the analysis of the remaining items.

Leave a Reply

avatar
  Subscribe  
Notify of